Navigation Links
New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities
Date:7/11/2014

CHAPEL HILL, N.C., July 11, 2014 /PRNewswire/ -- Patient engagement has become a critical component of pharmaceutical marketing and, consequently, organizations are turning to an assortment of marketing activities designed specifically for patients.

As part of this evolving approach to patient engagement, marketers have learned it's important to educate, communicate and engage patients throughout their experiences with a disease - from disease awareness to patient empowerment. By mapping the patient journey and employing a consumer marketing program that follows this path, marketing groups can more effectively engage with patients.

To better understand this strategic shift in patient marketing, Best Practices, LLC conducted a study to investigate how companies are adopting a "Patient Journey" framework to acquire, convert, support, and retain patients for their medical products. The resulting report, "Patient-Focused Marketing: Engagement Milestones along the Patient Journey," produced reliable industry metrics on current spending levels and investment allocation patterns for marketing to and communicating with patients.

The study employed a six-step framework to trace the patient journey and to identify what patient-focused initiatives, marketing activities, and investment levels are most effective for engaging patients during each phase of their journey.  On average, companies spend more than half their patient engagement funds during the first three stages of the patient journey - awareness, diagnosis and treatment consideration, according to the study. With the exception of the U.S. company segment, study participants focus their spend on the treatment consideration stage; diabetes companies place the highest emphasis here.

Marketing leaders can use this study to evaluate how their patient engagement programs compare with industry averages and trends.

Key topics addressed in this report include:

  • Investment in Patient-Focused Activities & Programs
  • Future Investment Levels in the Patient Journey
  • Investment within Patient Marketing, Foundation & Leadership Categories
  • Deployment of Patient-Focused Activities & Programs
  • Activities Timing Across the Patient Journey
  • Best Practices Shared by Benchmark Participants
  • Effective Patient Loyalty Programs
  • Pitfalls for Patient Marketers to Avoid

The research is based on a benchmarking survey instrument that engaged 22 leaders at 19 companies. Qualitative data came from in-depth interviews with seven participants. To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1298.htm.

For more information on other recent primary research studies, contact us at 919.403.0251. For related research, visit our Best Practices, LLC Web site at http://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Veran Medical Publishes Lung Cancer Patient Management Study
2. Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
3. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
4. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
5. First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
6. Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
7. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
8. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
9. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
10. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
11. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):